cyclophosphamide + vincristine + prednisone + cyclophosphamide + vincristine + prednisone + doxorubicin + methotrexate + cyclophosphamide + vincristine + etoposide

This multi-agent chemotherapy regimen is a risk-stratified protocol used in the St. Jude Children's Research Hospital 'Mature B-Cell Lymphoma And Leukemia Study III' for pediatric and young adult patients with newly diagnosed mature B-cell lymphoma or leukemia. The regimen is a sequential combination of small-molecule cytotoxic agents, including cyclophosphamide (an alkylating agent), vincristine (a vinca alkaloid), prednisone (a corticosteroid), doxorubicin (an anthracycline), methotrexate (an antifolate), and etoposide (a topoisomerase II inhibitor). It is derived from the LMB-96 protocol and is designed to improve outcomes through biology-focused study and risk-adapted therapy. The components work synergistically to disrupt DNA replication, inhibit microtubule polymerization, and induce apoptosis in malignant B-cells. In the clinical trial context, specific formulations such as vincristine sulfate liposome injection and pegylated liposomal doxorubicin may be utilized as part of the modified protocol.

Other names

Mature B-Cell Lymphoma And Leukemia Study III regimenmodified LMB-96 regimen